MX2020006494A - Anticuerpos de cadena pesada que se unen a cd22. - Google Patents

Anticuerpos de cadena pesada que se unen a cd22.

Info

Publication number
MX2020006494A
MX2020006494A MX2020006494A MX2020006494A MX2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A MX 2020006494 A MX2020006494 A MX 2020006494A
Authority
MX
Mexico
Prior art keywords
heavy chain
chain antibodies
antibodies binding
antibodies
sup
Prior art date
Application number
MX2020006494A
Other languages
English (en)
Inventor
Schooten Wim Van
Shelley Force Aldred
Katherine Harris
Heather Anne N Ogana
Laura Marie Davison
Udaya Rangaswamy
Nathan D Trinklein
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of MX2020006494A publication Critical patent/MX2020006494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen anticuerpos anti-CD22 de cadena pesada (p. ej., UniAbsTM) junto con métodos para elaborar dichos anticuerpos, composiciones, incluidas las composiciones farmacéuticas que comprenden dichos anticuerpos, y su uso para tratar trastornos de linfocitos B que se caracterizan por la expresión de CD22.
MX2020006494A 2017-12-22 2018-12-21 Anticuerpos de cadena pesada que se unen a cd22. MX2020006494A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609759P 2017-12-22 2017-12-22
PCT/US2018/067299 WO2019126756A1 (en) 2017-12-22 2018-12-21 Heavy chain antibodies binding to cd22

Publications (1)

Publication Number Publication Date
MX2020006494A true MX2020006494A (es) 2020-11-24

Family

ID=65041936

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006494A MX2020006494A (es) 2017-12-22 2018-12-21 Anticuerpos de cadena pesada que se unen a cd22.

Country Status (21)

Country Link
US (2) US11873336B2 (es)
EP (1) EP3728319A1 (es)
JP (2) JP7486421B2 (es)
KR (1) KR20200104342A (es)
CN (1) CN111683966B (es)
AU (1) AU2018392088A1 (es)
BR (1) BR112020012554A2 (es)
CA (1) CA3086665A1 (es)
CL (2) CL2020001703A1 (es)
CO (1) CO2020008925A2 (es)
CR (1) CR20200322A (es)
EA (1) EA202091557A1 (es)
EC (1) ECSP20042489A (es)
IL (1) IL275498A (es)
JO (1) JOP20200157A1 (es)
MX (1) MX2020006494A (es)
NI (1) NI202000050A (es)
PE (1) PE20201171A1 (es)
PH (1) PH12020550964A1 (es)
SG (1) SG11202005880XA (es)
WO (1) WO2019126756A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
BR112019026803A2 (pt) 2017-06-20 2020-06-30 Teneoone, Inc. anticorpos apenas de cadeia pesada anti-bcma
JP7486421B2 (ja) 2017-12-22 2024-05-17 テネオバイオ， インコーポレイテッド Ｃｄ２２に結合する重鎖抗体
CR20210622A (es) * 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
KR20210143097A (ko) * 2020-05-19 2021-11-26 (주)이노베이션바이오 Cd22에 특이적인 항체 및 이의 용도
CN116323948A (zh) * 2020-07-16 2023-06-23 南京传奇生物科技有限公司 Cd22结合分子及其用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
BR0110610A (pt) 2000-04-11 2003-04-29 Genentech Inc Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP3272770B1 (en) 2004-07-22 2023-12-20 Erasmus University Medical Center Rotterdam Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RS58217B1 (sr) 2007-04-03 2019-03-29 Amgen Res Munich Gmbh Interspecijski specifičan vezujući domen
NZ581396A (en) 2007-06-01 2012-07-27 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
AU2009294416B2 (en) 2008-09-19 2014-05-22 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
BRPI0919841A2 (pt) 2008-10-01 2014-11-18 Micromet Ag Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
US9034324B2 (en) 2009-03-10 2015-05-19 Biogen Idec Ma Inc. Anti-BCMA antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2012066058A1 (en) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents and methods for treating diseases that correlate with bcma expression
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ， インク． 二重特異性三鎖抗体様分子
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
KR20150004856A (ko) 2012-04-20 2015-01-13 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd3 결합 폴리펩타이드
CA2871764A1 (en) 2012-04-26 2013-10-31 Gerhard Frey Anti-cd22 antibodies
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013358958B2 (en) 2012-12-14 2018-09-20 Open Monoclonal Technology, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
RU2747011C2 (ru) 2014-11-20 2021-04-23 Ф.Хоффманн-Ля Рош Аг Общие легкие цепи и способы их применения
CN104710528B (zh) 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
IL260958B1 (en) 2016-02-03 2024-07-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
AU2017316604A1 (en) * 2016-08-24 2019-04-11 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
JP7254699B2 (ja) 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
BR112019026803A2 (pt) 2017-06-20 2020-06-30 Teneoone, Inc. anticorpos apenas de cadeia pesada anti-bcma
EP3642237A2 (en) 2017-06-20 2020-04-29 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
SG11201913175TA (en) 2017-06-30 2020-01-30 The United States Of America As Represented By The Secretary Anti-b-cell maturation antigen chimeric antigen receptors with human domains
RU2020112490A (ru) 2017-09-13 2021-10-13 Тенеобио, Инк. Антитела из тяжелых цепей, связывающиеся с эктоферментами
JP7486421B2 (ja) 2017-12-22 2024-05-17 テネオバイオ， インコーポレイテッド Ｃｄ２２に結合する重鎖抗体
EP3732199A1 (en) 2017-12-27 2020-11-04 TeneoBio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
MX2021000708A (es) 2018-07-20 2021-03-25 Teneobio Inc Anticuerpos de cadena pesada que se unen al cd19.
CA3113057A1 (en) 2018-09-21 2020-03-26 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
CR20210622A (es) 2019-06-14 2022-06-27 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
KR20220114559A (ko) 2019-12-18 2022-08-17 테네오포, 인코포레이티드 Cd38에 결합하는 중쇄 항체
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
JP2023532129A (ja) 2020-06-30 2023-07-26 テネオバイオ， インコーポレイテッド Ｂｃｍａに結合する多重特異性抗体
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
EP4298129A1 (en) 2021-02-26 2024-01-03 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
BR112023020450A2 (pt) 2021-04-06 2024-01-23 Teneobio Inc Anticorpos anti-cd19 e estruturas car-t
PE20240656A1 (es) 2021-04-16 2024-04-04 Teneobio Inc Anticuerpos anti-cd20 y estructuras car-t
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen

Also Published As

Publication number Publication date
PH12020550964A1 (en) 2021-03-22
CR20200322A (es) 2021-01-12
JOP20200157A1 (ar) 2022-10-30
CA3086665A1 (en) 2019-06-27
AU2018392088A2 (en) 2020-08-27
CL2022002247A1 (es) 2023-02-24
PE20201171A1 (es) 2020-10-28
CL2020001703A1 (es) 2020-11-06
WO2019126756A1 (en) 2019-06-27
AU2018392088A1 (en) 2020-08-13
NI202000050A (es) 2020-12-04
ECSP20042489A (es) 2020-11-30
RU2020124188A (ru) 2022-01-24
CO2020008925A2 (es) 2020-10-30
US20210095022A1 (en) 2021-04-01
US20240117046A1 (en) 2024-04-11
JP2024062992A (ja) 2024-05-10
BR112020012554A2 (pt) 2020-11-24
CN111683966A (zh) 2020-09-18
WO2019126756A9 (en) 2019-10-17
EP3728319A1 (en) 2020-10-28
SG11202005880XA (en) 2020-07-29
EA202091557A1 (ru) 2020-11-18
KR20200104342A (ko) 2020-09-03
IL275498A (en) 2020-08-31
CN111683966B (zh) 2023-07-11
US11873336B2 (en) 2024-01-16
JP7486421B2 (ja) 2024-05-17
JP2021506325A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
MX2020006494A (es) Anticuerpos de cadena pesada que se unen a cd22.
MX2023006380A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
MX2021012205A (es) Anticuerpos de cadena pesada que se unen al psma.
PH12017500803A1 (en) Anti-pd-1 antibodies
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
SG10201803042PA (en) Anti-tim-3 antibodies
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
WO2017091683A8 (en) Antibody molecules to april and uses thereof
TN2016000272A1 (en) Antibody molecules to pd-1 and uses thereof.
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
PH12018500379A1 (en) Biopharmaceutical compositions
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
MX2018005785A (es) Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
MX2022016342A (es) Union de anticuerpos multiespecificos a bcma.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.